1. Stocks
    2. /
  2. BioNTech SE (NASDAQ: BNTX)
    3. /

BioNTech SE (NASDAQ: BNTX) Share Price and News

$89.22 $-0.05 (-0.1%) 24 March 2026 at 5:43:02 am AEDT

BioNTech SE Chart and Price Data

About BioNTech Se

Last updated 24-03-2026, 05:43:02am AEDT
Current Price $89.22
Change $-0.05 (-0.1%)
Close Price $89.27
Open Price $89.41
Bid $89.21
Ask $89.35
Day Range $87.96 - $90.94
Year Range $79.52 - $124.00
Volume 846,576
Average Volume 1,210,300
Market Cap $22,435,812,258.00
Earnings Per Share $-5.23

BioNTech SE (NASDAQ: BNTX)
Latest News

success, high flyer, win, challenge
Share Market News

Dow Jones hits new record highs. Are ASX 200 shares next?

| Bernd Struben

The Dow Jones just hit new all-time highs. ASX 200 shares are still 9% below their record highs, but that…

Read more »

Group of young friends wearing facemasks dining out and raising glasses in a toast
Coronavirus News

COVID-19 over? Credit and debit card spend surges

| Tony Yoo

Commonwealth Bank research shows Australians have started splashing the dollars around. Is the coronavirus recession over?

Read more »

A hand holding a pin about to burst a balloon, indicating a crash or drop in asx shares
Share Market News

Will Pfizer's COVID-19 vaccine end the ASX tech share rally?

| Bernd Struben

With Pfizer's announcement of a promising COVID-19 vaccine, ASX tech shares are largely missing out on the global share market…

Read more »

International Stock News

Pfizer and BioNTech coronavirus vaccine accepted for rolling review in Canada

| Eric Volkman

Health Canada will determine BNT162b2's suitability for approval as clinical trial data comes in.

Read more »

person receiving coronavirus vaccine injection into the arm
International Stock News

3 reasons Pfizer and BioNTech will have coronavirus vaccine data before Moderna

| Brian Orelli, PhD

Different clinical trial designs gives the duo an advantage, but coming in first isn't the end goal for vaccine makers.

Read more »

doctor giving little boy vaccine injection in his arm
International Stock News

Johnson & Johnson (NYSE:JNJ) starts late-stage coronavirus vaccine clinical trial

| Brian Orelli, PhD

The phase 3 study of JNJ-78436735, which will enroll 60,000 participants, is underway.

Read more »

gloved hand injecting coronavirus vaccine into person's arm
International Stock News

Coronavirus vaccine trial adverse event was probably unrelated to treatment

| Brian Orelli, PhD

The paused clinical trial has already resumed.

Read more »

International Stock News

Pfizer says it could know if its COVID-19 vaccine candidate works in October

| Todd Campbell

The drugmaker's CEO said there was a more than 60% chance that they would know by the end of next…

Read more »

doctor making thumbs up gesture and holding vial labelled 'covid-19 vaccine' representing covid shares
International Stock News

The surefire vaccine winner following AstraZeneca's COVID-19 trial pause

| Keith Speights

Hint: It's not Moderna.

Read more »

International Stock News

What if more than one company wins the coronavirus vaccine race?

| Alex Carchidi

The ability to globally distribute a vaccine is as important as the vaccine itself. To the best-equipped victors go the…

Read more »

CSL share price represented by hand in blue glove picks out a vial labelled 'covid-19 vaccine' from a row of vials
International Stock News

Coronavirus vaccine race: 7 key things you'll want to know

| Keith Speights

Here are the answers to your top questions about where things stand with the development of COVID-19 vaccines.

Read more »

Patient wearing mask gets COVID vaccine injection
International Stock News

AstraZeneca coronavirus vaccine clinical trial paused

| Brian Orelli, PhD

One participant fell ill, but the connection to treatment with AZD122 is unclear.

Read more »

Profile

since

Note